We are live on ! Find out more
MRTX

Mirati Therapeutics, Inc. Common Stock
MRTX

Delisted

MRTX was delisted on the 22nd of January, 2024.

Back to rankings

238 hedge funds and large institutions have $9.58B invested in Mirati Therapeutics, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 90 increasing their positions, 81 reducing their positions, and 46 closing their positions.

New
Increased
Maintained
Reduced
Closed

190% more call options, than puts

Call options by funds: $261M | Put options by funds: $90M

25% more funds holding in top 10

Funds holding in top 10: 12 → 15 (+3)

12% more capital invested

Capital invested by funds: $8.55B → $9.58B (+$1.02B)

11% more repeat investments, than reductions

Existing positions increased: 90 | Existing positions reduced: 81

3% less funds holding

Funds holding: 245 → 238 (-7)

11% less first-time investments, than exits

New positions opened: 41 | Existing positions closed: 46

Holders
238
Holders Change
-7
Holders Change %
-2.86%
% of All Funds
4.17%
Holding in Top 10
15
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+25%
% of All Funds
0.26%
New
41
Increased
90
Reduced
81
Closed
46
Calls
$261M
Puts
$90M
Net Calls
+$171M
Net Calls Change
+$114M

Top Buyers

Rank Fund Capital Flow
1
Ameriprise
Ameriprise
Minnesota
+$188M
2
Invesco
Invesco
Georgia
+$56.4M
3
AG
Artal Group
Luxembourg
+$56.3M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$54.2M
5
APM
Avidity Partners Management
Texas
+$49.8M

Top Sellers

Rank Fund Capital Flow
1
FCM
Farallon Capital Management
California
-$106M
2
Millennium Management
Millennium Management
New York
-$70.9M
3
Citadel Advisors
Citadel Advisors
Florida
-$67.5M
4
BlackRock
BlackRock
New York
-$59.4M
5
HF
HRT Financial
New York
-$19.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
CCM
26
Camber Capital Management
Massachusetts
$79.6M +$8.04M +50,000 +13%
UBS AM
27
UBS AM
Illinois
$72M -$3.82M -23,751 -6%
CS
28
Credit Suisse
Switzerland
$70.2M +$123K +767 +0.2%
CS
29
Candriam SCA
Luxembourg
$67.8M +$6.05M +37,623 +11%
Assenagon Asset Management
30
Assenagon Asset Management
Luxembourg
$64.1M -$154K -959 -0.3%
Norges Bank
31
Norges Bank
Norway
$62.9M -$1.98M -12,315 -3%
RSCM
32
Rock Springs Capital Management
Maryland
$62.5M +$5.54M +34,429 +11%
Charles Schwab
33
Charles Schwab
California
$61.4M +$765K +4,757 +1%
PHS
34
PFM Health Sciences
California
$53.2M +$2.17M +13,499 +5%
Wells Fargo
35
Wells Fargo
California
$50.6M -$6.41M -39,830 -12%
Jennison Associates
36
Jennison Associates
New York
$46.4M +$14.4M +89,329 +52%
EAM
37
Eagle Asset Management
Florida
$45.9M +$41.8M +259,506 New
PAMS
38
Pictet Asset Management (Switzerland)
Switzerland
$44.2M +$40.2M +250,105 New
FCM
39
Farallon Capital Management
California
$42.2M -$106M -661,282 -73%
Goldman Sachs
40
Goldman Sachs
New York
$34.7M +$2.85M +17,692 +10%
SCM
41
Suvretta Capital Management
New York
$33.8M +$6.83M +42,436 +29%
Northern Trust
42
Northern Trust
Illinois
$33.6M -$6.91M -42,959 -18%
Bank of New York Mellon
43
Bank of New York Mellon
New York
$28.4M -$3.56M -22,120 -12%
N
44
Nuveen
North Carolina
$27.9M -$1.31M -8,142 -5%
Federated Hermes
45
Federated Hermes
Pennsylvania
$27.5M +$113K +700 +0.5%
RPAM
46
Rhenman & Partners Asset Management
Sweden
$26.5M -$2.41M -15,000 -9%
DCM
47
Driehaus Capital Management
Illinois
$26.3M +$13.8M +85,736 +136%
EAM
48
Eventide Asset Management
Massachusetts
$22.9M – – –
NIP
49
Nicholas Investment Partners
California
$21.2M +$230K +1,432 +1%
CAM
50
Cormorant Asset Management
Massachusetts
$21.2M -$8.85M -55,000 -31%
1
2
3 4 5

MRTX Hedge Fund Activity: Q3 2021 in Review

238 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q3 2021, worth a combined $9.58B — up 12% from $8.55B a quarter earlier.

Sellers outnumbered buyers: 46 funds closed out of MRTX and 41 opened new positions — a net loss of 5 holders — while 81 trimmed existing stakes and 90 added.

The largest buyer was Ameriprise, adding an estimated $188M. The largest seller was Farallon Capital Management, cutting an estimated $106M.

  • 238 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q3 2021, down from 245 in Q2 2021.
  • Funds reported $9.58B of Mirati Therapeutics, Inc. Common Stock stock for Q3 2021, up 12% quarter-over-quarter.
  • 41 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q3 2021 and 46 closed out, a net change of -5 holders.
  • The largest Mirati Therapeutics, Inc. Common Stock buyer in Q3 2021 was Ameriprise, an estimated $188M added.
  • The largest Mirati Therapeutics, Inc. Common Stock seller in Q3 2021 was Farallon Capital Management, an estimated $106M sold.

Based on aggregated 13F filings for Q3 2021.